ArticleProstate international2023
Irreversible electroporation for prostate cancer using PSMA PET-CT.
Article in Prostate international, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Is there a role of PSMA-PET in focal therapy planning and follow-up?Prostate cancer and prostatic diseases · 2026Pooled it
- The addition of PSMA PET in selecting candidates for prostate cancer focal therapy.BJUI compass · 2026Article
- Results from the PRESERVE trial: an editorial commentary.Translational andrology and urology · 2026Article
- Irreversible electroporation in focal therapy for prostate cancer: current status and future directions.Prostate international · 2026Review
- Irreversible electroporation for localized prostate cancer: risk-stratified oncologic outcomes and functional preservation.Prostate international · 2026Article
- Focal irreversible electroporation for the treatment of localised prostate cancer: a systematic review.Translational andrology and urology · 2025Review
- Article
- Review
- Article
- Irreversible Electroporation for the Focal Treatment of Prostate Cancer: A Systematic Review.The world journal of men's health · 2025Article
- Clinical significance of primary tumor progression in metastatic hormone-sensitive prostate cancer.Prostate international · 2025Article
- Comparison of the Effects of DOTA and NOTA Chelators onDiagnostics (Basel, Switzerland) · 2023Article
- Review
- Diagnostic performance of MRI for prediction of recurrent prostate cancer after high-intensity focused ultrasound: a systematic review and meta-analysis.Prostate international · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To demonstrate the clinical usefulness of prostate-specific membrane antigen (PSMA) positron emission tomography (PET) computerized tomography (CT) for irreversible electroporation (IRE) in prostate cancer patients. Methods: From January to May 2021, 17 men were diagnosed with localized prostate cancer through preoperative mpMRI and [ Results: The mean age of the patients was 66.1 ± 9.3 with a median PSA of 7.5 ng/ml. After the treatment, PSA nadir was 4.06 ± 3.4, and 11 (64.7%) achieved decline of PSA more than 50% from the baseline. Rate of negative biopsy for prostate cancer is 88% (15/17) at 12 months MR fusion biopsy after the IRE treatment. Among the relapsed cases, 1 (6.9%) patient recurred at margin of treated area, and 1 (6.9%) patient was from outfield recurrence. When excluding initial four patients, none of the patients had cancer recur. Conclusions: When treating with IRE focal therapy, PSMA-PET CT is a potentially valuable diagnostic approach for localizing prostate cancer; it supports the detection of lesions with conventional mpMRI, enabling to perform the procedure more completely.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.